PL369010A1 - Sposoby, kompozycje i zestawy dotyczące chitynaz i chitynopodobnych cząsteczek oraz choroby zapalnej - Google Patents

Sposoby, kompozycje i zestawy dotyczące chitynaz i chitynopodobnych cząsteczek oraz choroby zapalnej

Info

Publication number
PL369010A1
PL369010A1 PL02369010A PL36901002A PL369010A1 PL 369010 A1 PL369010 A1 PL 369010A1 PL 02369010 A PL02369010 A PL 02369010A PL 36901002 A PL36901002 A PL 36901002A PL 369010 A1 PL369010 A1 PL 369010A1
Authority
PL
Poland
Prior art keywords
chitinases
chitinase
molecules
compositions
methods
Prior art date
Application number
PL02369010A
Other languages
English (en)
Inventor
Jack A. Elias
Zhou Zhu
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of PL369010A1 publication Critical patent/PL369010A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2442—Chitinase (3.2.1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01014—Chitinase (3.2.1.14)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL02369010A 2001-07-24 2002-07-23 Sposoby, kompozycje i zestawy dotyczące chitynaz i chitynopodobnych cząsteczek oraz choroby zapalnej PL369010A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30743201P 2001-07-24 2001-07-24

Publications (1)

Publication Number Publication Date
PL369010A1 true PL369010A1 (pl) 2005-04-18

Family

ID=23189747

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02369010A PL369010A1 (pl) 2001-07-24 2002-07-23 Sposoby, kompozycje i zestawy dotyczące chitynaz i chitynopodobnych cząsteczek oraz choroby zapalnej

Country Status (13)

Country Link
US (6) US7214373B2 (pl)
EP (1) EP1418813A4 (pl)
JP (1) JP2006508014A (pl)
KR (1) KR20040053100A (pl)
AU (1) AU2002319680B2 (pl)
BR (1) BR0211468A (pl)
CA (1) CA2454342A1 (pl)
HU (1) HUP0400659A3 (pl)
IL (2) IL160000A0 (pl)
MX (1) MXPA04000769A (pl)
NO (1) NO20040330L (pl)
PL (1) PL369010A1 (pl)
WO (1) WO2003009808A2 (pl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031582A2 (en) * 2001-10-09 2003-04-17 Genentech, Inc. Novel acidic mammalian proteins and polynucleotides encoding the same
US20040170621A1 (en) * 2002-08-30 2004-09-02 Roodman G. David Method of resisting osteoclast formation
US7364846B2 (en) * 2002-10-11 2008-04-29 Molecular Devices Corporation Gene expression profiling from FFPE samples
WO2004092404A2 (en) * 2003-04-11 2004-10-28 Wyeth Inhibitors of acidic mammalian chitinase as asthma therapeutics
US20050214297A1 (en) * 2004-02-25 2005-09-29 Medimmune, Inc. Methods and compositions relating to chitinases and chitinase-like molecules and modulation of osteoclasts
JP2008546805A (ja) 2005-06-23 2008-12-25 メディミューン，エルエルシー 最適な凝集および断片化プロフィールを有する抗体製剤
WO2007027748A2 (en) * 2005-08-31 2007-03-08 Medimmune, Inc. C/clp antagonists and methods of use thereof
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
US20090010942A1 (en) * 2007-05-18 2009-01-08 Wyeth Novel primate chitinases and uses therefor
JP5346957B2 (ja) 2008-01-23 2013-11-20 ヘルレフ ホスピタル 不特定疾患の汎用マーカーとしてのｙｋｌ−４０
US20110070601A1 (en) * 2008-01-23 2011-03-24 Rigshospitalet Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker ykl-40
AU2009276223B2 (en) * 2008-08-01 2015-04-02 Simon Fraser University Selective glycosidase inhibitors and uses thereof
JP2012501456A (ja) * 2008-08-28 2012-01-19 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
EP2324354B1 (en) * 2008-08-29 2014-07-16 Astute Medical, Inc. Methods for prognosis of acute renal failure
CN102317783A (zh) 2008-09-15 2012-01-11 海莱乌医院 作为胃肠癌的标记的ykl-40
NZ592365A (en) * 2008-10-21 2014-08-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ592358A (en) 2008-10-21 2013-05-31 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure using tissue inhibitor of metalloproteinase 2 (timp-2)
CN104330574B (zh) 2008-11-10 2017-04-12 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
MX2011005379A (es) * 2008-11-22 2011-06-09 Astute Medical Inc Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal.
US7851616B2 (en) * 2008-12-04 2010-12-14 Mingchi University Of Technology Development of asthma therapy with rAAV-mediated AMCase shRNA
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ598034A (en) 2009-08-07 2014-06-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10324093B2 (en) 2009-11-07 2019-06-18 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2592386T3 (es) 2009-12-20 2016-11-29 Astute Medical, Inc. Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
WO2011097539A1 (en) 2010-02-05 2011-08-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011162819A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2539712A4 (en) 2010-02-26 2013-09-18 Astute Medical Inc METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
CA2804297A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5861194B2 (ja) 2010-12-23 2016-02-16 アレクトス・セラピューティクス・インコーポレイテッド 選択的グルコシダーゼインヒビターおよびその使用
WO2012129651A1 (en) 2011-03-31 2012-10-04 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
US9701693B2 (en) 2011-06-27 2017-07-11 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
EP3540440B1 (en) 2011-12-08 2022-09-28 Astute Medical, Inc. Methods and uses for evaluating renal injury and renal status
WO2013130594A1 (en) * 2012-02-27 2013-09-06 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9809537B2 (en) 2012-08-31 2017-11-07 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014032185A1 (en) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
AU2013337570B2 (en) 2012-10-31 2018-01-18 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
EP2946211B1 (en) 2013-01-17 2018-02-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
GB2521675B (en) 2013-12-31 2015-11-11 Houman Taheri Amlashi Generating electricity
JP6209289B2 (ja) * 2014-10-22 2017-10-04 サントリーホールディングス株式会社 環状ジペプチドを有効成分とする皮膚保湿機能改善剤
EP3233106B1 (en) 2014-12-18 2023-02-01 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JPWO2016136991A1 (ja) * 2015-02-27 2017-12-07 味の素株式会社 唾液中マーカータンパク質を用いた低栄養状態の判定方法、及びそれに使用する診断薬
CA3026502A1 (en) 2016-06-06 2017-12-14 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
CA3078461A1 (en) 2017-08-17 2019-02-21 Brown University Methods and compositions relating to the treatment of fibrosis
JP7267562B2 (ja) * 2018-05-21 2023-05-02 学校法人東京薬科大学 免疫調節作用を有する単球およびその使用方法
CN108926708A (zh) * 2018-07-31 2018-12-04 张家港市第人民医院 过敏性鼻炎小鼠模型复制方法及应用
WO2021203051A1 (en) * 2020-04-03 2021-10-07 Standard Of Care Corporation Aerosolized hyaluronidase and/or 4-methylumbelliferone compositions and methods of using same to treat respiratory diseases or disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69010388T2 (de) * 1989-04-27 1994-10-20 Ajinomoto Kk Demethylallosamidin und ein Verfahren zu seiner Herstellung.
JP3063930B2 (ja) * 1991-01-31 2000-07-12 味の素株式会社 アロサミジン化合物及びその製造法
AU7205894A (en) * 1993-06-08 1995-01-03 Neogenix, Inc. Purified natural and synthetic compounds for the treatment of osteoarthritis
US7229770B1 (en) 1998-10-01 2007-06-12 The Regents Of The University Of California YKL-40 as a marker and prognostic indicator for cancers
CA2164498C (en) 1993-07-09 2007-09-11 Paul A. Price Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
IL115744A (en) * 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
JP3634891B2 (ja) 1995-04-06 2005-03-30 株式会社海洋バイオテクノロジー研究所 キチナーゼ阻害物質
US5773259A (en) * 1996-03-20 1998-06-30 Smithkline Beecham Corporation Tissue remodeling proteins
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
WO1997036917A1 (en) 1996-03-29 1997-10-09 Smithkline Beecham Corporation Chitotriosidase
EP0805206A3 (en) * 1996-05-03 1999-09-15 Smithkline Beecham Corporation Human cartilage glycoprotein
US5811535A (en) * 1996-08-09 1998-09-22 Smithkline Beecham Corporation Human cartilege gp39-like gene
IL122233A (en) * 1996-12-06 2001-04-30 Akzo Nobel Nv Method of generating monoclonal antibodies to cell wall and pharmaceutical preparations and diagnostic agents containing them
US6200951B1 (en) 1998-03-12 2001-03-13 Icos Corporation Chitinase chitin-binding fragments
US6060590A (en) * 1998-03-31 2000-05-09 The Regents Of The University Of California Chitinase related proteins and methods of use
EP1100526A2 (en) 1998-07-23 2001-05-23 Akzo Nobel N.V. USE OF HC gp-39 IN IMMUNE DISEASES
JP2002521388A (ja) 1998-07-23 2002-07-16 アクゾ・ノベル・エヌ・ベー 自己免疫疾患の免疫療法に使用するための新規ペプチド
JP2000327575A (ja) 1999-05-26 2000-11-28 Teika Seiyaku Kk ジケトピペラジン誘導体含有炎症疾患治療剤および新規なジケトピペラジン誘導体
EP1231270B1 (en) * 1999-11-15 2006-05-31 Takeda Pharmaceutical Company Limited Novel protein and dna thereof
AU9373501A (en) 2000-08-14 2002-02-25 Akzo Nobel Nv Use of antibodies against specific mhc-peptide complexes
AU2001283327A1 (en) * 2000-08-14 2002-02-25 Human Genome Sciences, Inc. 8 human secreted proteins
DE10046267A1 (de) 2000-09-19 2002-03-28 Bayer Ag Verwendung von Riboflavin und Flavinderivaten als Inhibitoren von Chitinasen
US20030087414A1 (en) * 2001-11-02 2003-05-08 Aerts Johannes Maria Franciscus Gerardus Mammalian mucinase, its recombinant production, and its use in therapy or prophylaxis against diseases in which mucus is involved or infectious diseases
US20040170621A1 (en) * 2002-08-30 2004-09-02 Roodman G. David Method of resisting osteoclast formation
EP1856153B1 (en) 2005-02-28 2010-12-29 Bio-Y A/S Ykl-40 monoclonal antibodies

Also Published As

Publication number Publication date
HUP0400659A2 (hu) 2005-02-28
US7214373B2 (en) 2007-05-08
HUP0400659A3 (en) 2005-06-28
WO2003009808A3 (en) 2003-09-04
JP2006508014A (ja) 2006-03-09
EP1418813A2 (en) 2004-05-19
KR20040053100A (ko) 2004-06-23
CA2454342A1 (en) 2003-02-06
IL160000A0 (en) 2004-06-20
US20030049261A1 (en) 2003-03-13
IL160000A (en) 2010-06-16
EP1418813A4 (en) 2009-03-04
NO20040330L (no) 2004-03-09
WO2003009808A2 (en) 2003-02-06
US20090149410A1 (en) 2009-06-11
US20130136751A1 (en) 2013-05-30
US20090162347A1 (en) 2009-06-25
BR0211468A (pt) 2004-11-23
US8679503B2 (en) 2014-03-25
US20060063728A1 (en) 2006-03-23
AU2002319680B2 (en) 2008-04-10
MXPA04000769A (es) 2005-09-21
US20090148539A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
HUP0400659A3 (en) Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease
FI20021772A (fi) Uudet hiilihydraattikoostumukset ja menetelmä niiden valmistamiseksi
EP1651053A4 (en) COMPOSITIONS AND METHODS FOR FROZEN PASTA COMPOSITIONS READY TO BE COOKED
WO2006096490A3 (en) ANTI-MAdCAM ANTIBODY COMPOSITIONS
ZA200505997B (en) Laundry cleansing and conditioning compositions
GB0104153D0 (en) Improvements in or relating to organic compositions
EP1668024A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES INCLUDING INFLAMMATORY SUFFERING
IL185531A0 (en) Topical gel compositions
GB0126347D0 (en) Improvements in or relating to organic compositions
GB0130419D0 (en) Improvements in or relating to organic compositions
EP1667730A4 (en) COMPOSITIONS AND METHOD FOR TREATING INFLAMMATORY LUNG DISEASE
FR2831433B1 (fr) Composition topique solide
EP1613269A4 (en) COMPOSITIONS, METHODS AND KITS RELATING TO CLEARING HER-2
EP1940377A4 (en) TOPICAL AEROSPECTIVE COMPOSITIONS OF N, 2,3-TRIMETHYL-2-ISOPROPYLBUTAMIDE AND METHOD OF USE THEREOF
GB0403534D0 (en) Stable detergent composition and process to prepare the same
AU2001268232A1 (en) Compositions, methods, and kits relating to resistin-like molecules
PT1966099E (pt) Composição, frita, esmalte e componentes cerâmicos e processos para os fabricar
AU2002253889A1 (en) Compositions and methods for identifying, characterizing, optimizing and using ligands to transcytotic molecules
GB0327091D0 (en) Improvements in or relating to compositions
AU2002239739A1 (en) Compositions, methods and kits relating to remodelin
GB0112779D0 (en) Improvements in or relating to organic compositions
GB0126064D0 (en) Improvements in or relating to organic compositions
GB0124728D0 (en) Improvements in or relating to compositions
AU2002360531A1 (en) Methods and compositions to treat cardiovascular disease using 1419, 58765 and 2201
AU2003228737A8 (en) Compositions and methods relating to abca1-mediated cholesterol efflux

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)